Table 1.
Characteristics of Primary Cohort Participants
| Sample Size | n = 40 |
|---|---|
| DAA therapy regimen: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin | |
| DAA therapy duration, No. (%) | |
| 12-week | 6 (15) |
| 24-week | 34 (85) |
| ART regimen, No. (%) | |
| Integrase inhibitor based (RAL or DTG) | 22 (55) |
| Protease inhibitor (DRV or ATV) | 18 (45) |
| HCV genotype, No. (%) | |
| 1a | 6 (40) |
| 1b | 4 (27) |
| 2 | 2 (13) |
| 3 | 2 (13) |
| 4 | 1 (7) |
| Plasma HCV RNA level, IU/L | 2 790 000 (1 020 000–6 065 000) |
| Serum albumin level, g/dL | 4.3 (4.1–4.6) |
| Serum ALT level, IU/L | 48 (28–73) |
| Serum AST level, IU/L | 42 (31–58) |
| Platelets, K/μL | 217 (172–238) |
| APRI, AST/PLT index, No. (%) | |
| <0.4 | 31 (84) |
| 0.4–1.5 | 6 (16) |
| >1.5 | 0 (0) |
| FIB-4 index score | 1.4 (0.9–2.2) |
| FibroScan score | 6.4 (5.1–13.6) |
| Cirrhosis state, No. (%) | |
| Cirrhotics | 6 (15) |
| Noncirrhotics | 34 (85) |
| CD4, cells/mm3 | 622 (456–827) |
| Age, y | 53 (45–58) |
| Gender, No. (%) | |
| Male | 29 (73) |
| Female | 11 (27) |
| Race/ethnicity, No. (%) | |
| Black | 16 (40) |
| White | 8 (40) |
| Hispanic | 16 (20) |
Data are presented as median (interquartile range), unless otherwise indicated.
Abbreviations: APRI, AST to Platelet Ratio Index; ART, antiretroviral therapy; AST, aspartate transaminase; ATV, atazanavir; DAA, direct-acting antiviral; DRV, darunavir; DTG, dolutegravir; HCV, hepatitis C virus; PLT, platelet; RAL, raltegravir.